Predapox

Indication :

Predapox is indicated for the treatment of premature ejaculation (PE) in adult men aged 18 to 64 years.
Predapox should only be prescribed to patients who meet all the following criteria:
•An intravaginal ejaculatory latency time (IELT) of less than two minutes; and
•Persistent or recurrent ejaculation with minimal sexual stimulation before, on, or shortly after penetration and
before the patient wishes; and
•Marked personal distress or interpersonal difficulty as a consequence of PE; and
•Poor control over ejaculation; and
•A history of premature ejaculation in the majority of intercourse attempts over the prior 6 months.
Predapox should be administered only as on-demand treatment before anticipated sexual activity. Predapox should
not be prescribed to delay ejaculation in men who have not been diagnosed with PE.

Composition :

Each 30 mg film-coated tablet contains Dapoxetine hydrochloride 33.581 mg equivalent to 30 mg Dapoxetine.
Each 60 mg film-coated tablet contains Dapoxetine Hydrochloride 67.162 mg eq to 60 mg Dapoxetine.
Excipient with known effect: For the full list of excipients, see section 6.1.